In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Plus Therapeutics Inc (NASDAQ: PSTV) closed at $0.6 up 6.69% from its previous closing price of $0.56. In other words, the price has increased by $6.69 from its previous closing price. On the day, 8.42 million shares were traded. PSTV stock price reached its highest trading level at $0.63 during the session, while it also had its lowest trading level at $0.5671.
Ratios:
For a deeper understanding of Plus Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 17, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $9.
On January 25, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $8.Ladenburg Thalmann initiated its Buy rating on January 25, 2021, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 04 ’25 when Sims Andrew John Hugh MacIntyr bought 20,000 shares for $0.51 per share. The transaction valued at 10,200 led to the insider holds 68,138 shares of the business.
Lenk Robert P bought 110,000 shares of PSTV for $53,779 on Aug 22 ’25. The Director now owns 139,327 shares after completing the transaction at $0.49 per share. On May 15 ’25, another insider, Petersen Greg, who serves as the Director of the company, bought 36,666 shares for $0.55 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTV now has a Market Capitalization of 82223800 and an Enterprise Value of 72043800. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.63 while its Price-to-Book (P/B) ratio in mrq is 15.58. Its current Enterprise Value per Revenue stands at 13.702 whereas that against EBITDA is -5.56.
Stock Price History:
The Beta on a monthly basis for PSTV is 0.82, which has changed by -0.53125 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, PSTV has reached a high of $2.31, while it has fallen to a 52-week low of $0.16. The 50-Day Moving Average of the stock is 1.57%, while the 200-Day Moving Average is calculated to be -2.57%.
Shares Statistics:
For the past three months, PSTV has traded an average of 18.59M shares per day and 6877160 over the past ten days. A total of 137.43M shares are outstanding, with a floating share count of 136.95M. Insiders hold about 0.35% of the company’s shares, while institutions hold 5.82% stake in the company. Shares short for PSTV as of 1763078400 were 7773908 with a Short Ratio of 0.42, compared to 1760486400 on 1937613. Therefore, it implies a Short% of Shares Outstanding of 7773908 and a Short% of Float of 5.6599997.
Earnings Estimates
The market rating for Plus Therapeutics Inc (PSTV) is a result of the insights provided by 2.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.15 and -$0.3 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$0.14, with 2.0 analysts recommending between -$0.13 and -$0.15.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $1.64M this quarter.It ranges from a high estimate of $2.53M to a low estimate of $1M. As of. The current estimate, Plus Therapeutics Inc’s year-ago sales were $1.41MFor the next quarter, 3 analysts are estimating revenue of $1.5M. There is a high estimate of $2M for the next quarter, whereas the lowest estimate is $1M.
A total of 3 analysts have provided revenue estimates for PSTV’s current fiscal year. The highest revenue estimate was $6.37M, while the lowest revenue estimate was $4.8M, resulting in an average revenue estimate of $5.47M. In the same quarter a year ago, actual revenue was $5.82MBased on 3 analysts’ estimates, the company’s revenue will be $6.09M in the next fiscal year. The high estimate is $10.27M and the low estimate is $4M.
